Welcome to our dedicated page for American Well SEC filings (Ticker: AMWL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
American Well Corporation filings document the company’s SaaS-based technology-enabled healthcare platform, operating results, customer agreements, governance, and equity-compensation structure. Its Form 8-K filings include earnings reports for quarterly and annual periods, material definitive agreements, board changes, and related exhibit disclosures.
AMWL filings also describe commercial arrangements tied to digital care delivery, including the company’s operation of a white-labeled platform under the LiveHealth Online brand for Elevance Health and related clinical-provider access through Online Care Group. Proxy materials cover director elections, executive compensation, equity awards, stockholder voting matters, and board governance for the public company.
American Well Corporation reported lower revenue but a much smaller loss for the quarter ended June 30, 2026. Revenue fell 27% year over year to $52.0 million, driven mainly by a drop in platform subscription fees (to $25.7 million) and “other” services and Carepoint device revenue, partly offset by higher visit revenue of $24.4 million.
Total costs and operating expenses declined 33% to $61.6 million as management reduced headcount across functions and cut consulting, marketing, and legal spend. Net loss attributable to Amwell narrowed to $9.9 million from $19.7 million, improving loss per share to $0.59 from $1.24. Adjusted EBITDA improved to a loss of $1.2 million from $4.7 million. For the first half of 2026, net loss attributable to Amwell was $20.8 million versus $38.4 million a year earlier.
Operating cash flow turned positive at $9.7 million for the six-month period, compared with a $29.8 million outflow in 2025, and cash, cash equivalents and restricted cash rose to $196.7 million. Results also reflect a $3.4 million impairment from abandoning the corporate headquarters right-of-use asset and a $7.0 million gain from contingent consideration on a prior divestiture. Client usage softened, with 1.9 million visits in the first half of 2026 versus 2.5 million a year earlier, and a single client represented 65% of accounts receivable, underscoring concentration risk.
American Well Corporation reported Q2 2026 revenue of $52.0 million, at the top of its guidance range but below $70,898 thousand a year earlier. Subscription revenue was $25.7 million and Amwell Medical Group visit revenue $24.4 million, with 0.8 million total visits. Gross margin was 53%. Net loss was ($9.6) million, improving from $10.3 million in Q1 2026, and adjusted EBITDA narrowed to a ($1.2) million loss from $3.1 million.
The company noted operating cash inflows in the first half of 2026 and highlighted having no debt. For 2026, Amwell now guides revenue to $200–$205 million, up from $195–$205 million, and expects adjusted EBITDA of a ($9)–($7) million loss, improved from a ($16)–($12) million loss range. Q3 2026 guidance calls for revenue of $46–$48 million and adjusted EBITDA of a ($5)–($3) million loss, while reiterating an objective of positive cash flow from operations in Q4 2026.
American Well Corporation changed its external auditor. On July 14, 2026, the Audit Committee dismissed PricewaterhouseCoopers LLP as the independent registered public accounting firm and appointed BDO USA, P.C. as the new independent registered public accounting firm.
American Well states that PwC’s audit reports on the company’s financial statements for the fiscal years ended December 31, 2025 and 2024 contained no adverse opinions, disclaimers, or qualifications and that there were no disagreements or reportable events under Item 304(a) of Regulation S‑K during those periods and through July 14, 2026. PwC has been asked to provide a letter to the SEC regarding these disclosures, filed as Exhibit 16.1 and dated July 20, 2026.
American Well Corporation reappointed Stephen Schlegel as a Class III director on July 11, 2026, for a term expiring at the company’s 2029 annual meeting of stockholders. Shortly before this, on July 8, 2026, he resigned as a Class II director.
The company states that his resignation and reappointment were undertaken solely to rebalance the three director classes so they are approximately equal in size, as required by NYSE listing standards, and not due to any disagreement over operations, policies, or practices. His committee assignments and compensation arrangements remain unchanged, with further background information referenced in the definitive proxy statement on Schedule 14A filed on April 24, 2026.
American Well Corp Chief Accounting Officer Paul Francis McNeice reported an open-market sale of 653 shares of Class A common stock at $9.33 per share on July 1, 2026. According to the footnote, this automatic “sell to cover” trade was made solely to pay taxes on vested restricted stock units and was not a discretionary transaction. After the sale, he directly held 9,851 shares.
American Well Corp Chief Financial Officer Mark Hirschhorn reported a tax-related sale of 4,299 shares of Class A Common Stock. The shares were sold in an open-market transaction at $9.33 per share.
According to the disclosure, the sale was an automatic “sell to cover” transaction to pay tax liabilities from the vesting and settlement of restricted stock units on July 1, 2026, and did not represent a discretionary trade. After the sale, Hirschhorn directly owned 238,939 shares, indicating he retained the vast majority of his holdings.
American Well Corp’s Chief Product & Technology Officer, Dmitry Zamansky, sold 8,460 shares of Class A Common Stock at $9.33 per share. According to the filing, the sale was an automatic “sell to cover” transaction to pay taxes from restricted stock units vesting on July 1, 2026, and was not a discretionary trade. After the transaction, he directly holds 232,620 shares.
American Well Corp President, International Phyllis Gotlib reported an automatic sale of Class A Common Stock to cover taxes from vested restricted stock units. On July 1, 2026, 6,677 shares were sold in the open market at $9.33 per share through a non-discretionary “sell to cover” transaction.
After this sale, Gotlib directly holds 152,754 Class A shares. In addition, 114,920 Class A shares are reported as indirectly owned through her husband. The filing reflects a tax-related transaction rather than a discretionary change in investment exposure.
American Well Corporation filed a Form 144 reporting Class A Common Stock related to restricted stock unit vesting effective 07/01/2026. The notice identifies 6,301 RSUs vesting on 07/01/2026 and discloses prior sales of 10,761 shares on 06/01/2026 for $104,800.30.
American Well Corporation filed a Form 144 reporting proposed sales tied to a restricted stock unit vesting and a recent disposition. The filing lists 18,132 shares from a 07/01/2026 RSU vesting and notes 5,575 shares sold on 04/01/2026 for $29,563.67.